Brokerages Set Entasis Therapeutics Holdings Inc (NASDAQ:ETTX) Price Target at $9.50

Entasis Therapeutics Holdings Inc (NASDAQ:ETTX) has received a consensus recommendation of “Buy” from the seven brokerages that are covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $6.60.

A number of brokerages recently issued reports on ETTX. BMO Capital Markets decreased their target price on shares of Entasis Therapeutics from $15.00 to $5.00 and set an “outperform” rating on the stock in a research report on Friday, May 8th. CSFB reaffirmed an “outperform” rating and set a $8.00 price target on shares of Entasis Therapeutics in a research note on Sunday, June 21st. Zacks Investment Research downgraded shares of Entasis Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, June 16th. HC Wainwright cut their price target on shares of Entasis Therapeutics from $18.00 to $5.00 and set a “buy” rating on the stock in a research note on Tuesday, April 14th. Finally, ValuEngine downgraded shares of Entasis Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, March 18th.

In other Entasis Therapeutics news, major shareholder Innoviva, Inc. bought 12,677,490 shares of the business’s stock in a transaction dated Thursday, June 11th. The shares were acquired at an average price of $2.50 per share, with a total value of $31,693,725.00. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 15.40% of the company’s stock.

A hedge fund recently raised its stake in Entasis Therapeutics stock. Renaissance Technologies LLC grew its holdings in Entasis Therapeutics Holdings Inc (NASDAQ:ETTX) by 42.9% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 25,300 shares of the company’s stock after acquiring an additional 7,600 shares during the period. Renaissance Technologies LLC owned about 0.19% of Entasis Therapeutics worth $126,000 as of its most recent SEC filing. Institutional investors own 56.90% of the company’s stock.

NASDAQ ETTX traded up $0.07 during mid-day trading on Friday, reaching $2.94. 74,956 shares of the stock were exchanged, compared to its average volume of 143,396. Entasis Therapeutics has a 1-year low of $1.75 and a 1-year high of $9.25. The business’s fifty day simple moving average is $2.74 and its 200 day simple moving average is $3.83. The stock has a market capitalization of $41.94 million, a PE ratio of -0.84 and a beta of 2.09. The company has a debt-to-equity ratio of 0.04, a quick ratio of 5.67 and a current ratio of 5.67.

Entasis Therapeutics (NASDAQ:ETTX) last announced its earnings results on Thursday, May 7th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.00) by ($0.15). On average, analysts anticipate that Entasis Therapeutics will post -2.27 EPS for the current year.

About Entasis Therapeutics

Entasis Therapeutics Holdings, Inc operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products. The firm develops a portfolio of innovative cures for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin.

Featured Article: What is a Buy-Side Analyst?

Analyst Recommendations for Entasis Therapeutics (NASDAQ:ETTX)

Receive News & Ratings for Entasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entasis Therapeutics and related companies with's FREE daily email newsletter.